Carbocisteine Quality Study: Impurity Sources, Sulfoxidation Metabolism, and Reference Standard Selection

1. Mechanistic Differences Determined by Structure

Carbocisteine is a mature product in the Chinese respiratory field, but its market base does not match its research intensity: for oral solutions alone, sales in Chinese urban public hospitals and county-level public hospitals were approximately RMB 670 million in 2023 (Menet data); and although carbocisteine tablets have more than one hundred domestic approvals, the number of companies that had passed generic drug consistency evaluation remained in the single digits by mid-2024. For upstream suppliers, this gap means that demand for impurity profile research and analytical method development continues to be released.

Among sulfur-containing mucoactive drugs, the mechanism of N-acetylcysteine (NAC) is clear: the free sulfhydryl group reduces the intermolecular disulfide bonds of mucin, depolymerizing the sputum network structure and reducing viscosity.

Carbocisteine (Carbocisteine, CAS 638-23-3, C₅H₉NO₄S, molecular weight 179.19) acts through a different pathway. Its chemical entity is S-carboxymethyl-L-cysteine; the hydrogen on the sulfhydryl group of the cysteine side chain has been replaced by a carboxymethyl group, and the molecule contains no free sulfhydryl group.

Carbocisteine

The UK medicines review document (MHRA/SCOP) states that carbocisteine is a derivative whose disulfide group is blocked by a carboxylic acid residue, that its direct mucolytic effect may be extremely limited or even nonexistent, and that its main action is considered to occur at the metabolic level of mucus-secreting cells — in the mucus produced under its action, the sialomucin content increases while the fucomucin content decreases.

This structural feature is the chemical basis for classifying carbocisteine as a mucoregulator rather than a mucolytic: its target is the secretory metabolism of goblet cells, not the sputum itself. Recent studies have further extended its action to the regulation of MUC5B / MUC5AC expression imbalance and CFTR-related chloride and glutathione efflux.

Note on configuration labeling: carbocisteine is an L-cysteine derivative, with the IUPAC name (2R)-2-amino-3-[(carboxymethyl)sulfanyl]propanoic acid — according to the CIP rules, the priority order of the substituents on the sulfur atom makes its chiral center labeled (R). The coexistence of the "L-configuration" and the "(R)-label" is not a typographical error, but an inherent feature of cysteine-type compounds, and is a common source of misjudgment during reference standard selection and COA verification. Its enantiomer (D-form / (S)-configuration, CAS 50698-76-5) has a molecular weight exactly identical to the main component and can be distinguished by chiral chromatography.

2. Sulfoxidation Metabolic Polymorphism

Carbocisteine was once used as a probe drug in drug metabolism studies to investigate the polymorphic sulfoxidation capacity of human populations toward sulfur-containing drugs (Hoffmann et al., 1991).

Main metabolic pathway: using capillary gas chromatography-mass spectrometry with stable isotope-labeled analogs as internal standards, a human study identified three nitrogen-free metabolites, among which thiodiglycolic acid (TDGA) accounted for an average of 19.8% of the administered dose within 24 hours, and thiodiglycolic acid sulfoxide (TDGA-SO) accounted for an average of 13.3%.

Polymorphic metabolite: in addition, there is a urinary metabolite with polymorphic characteristics — about 7.5%–10% of individuals in two subject populations excreted only trace amounts, and the inter-individual difference in excretion was estimated to exceed two thousand fold; this metabolite was isolated and identified as S-(carboxymethylthio)-L-cysteine (Biochem Pharmacol, 1991).

Circadian rhythm influence: when a single 750 mg dose was administered at 8:00 AM, the main metabolite in urine samples from 8:00 to 16:00 was carbocisteine S-oxide, which shifted to S-(carboxymethylthio)-L-cysteine from 16:00 to midnight; when administered at midnight, the main metabolite from midnight to 8:00 the next morning was TDGA. The study concluded that the time of administration has a significant effect on the type of S-oxidation metabolites in urine (Steventon, 1999).

Analytical significance of the above metabolic features: current views hold that the thioether form is the active species, while the oxidized sulfoxide metabolite is inactive. A related correspondence in The Lancet further pointed out that the drug effect depends on two cytoplasmic enzymes, cysteine dioxygenase and phenylalanine-4-hydroxylase; highly efficient sulfoxidizers rapidly generate inactive oxygenated metabolites, weakening the drug effect, whereas weak sulfoxidizers are exposed to the active thioether for a longer time.

From this, a direct conclusion can be drawn: the (R)-sulfoxide and (S)-sulfoxide of carbocisteine should be controlled as two independent analytical targets. The two are diastereomers formed after the sulfur atom constitutes a chiral center, with differences in both chromatographic behavior and biological significance. The establishment of pharmacokinetic and metabolite quantification methods requires chromatographic peak assignment using the diastereomer mixture, and structural confirmation using single-configuration reference standards.

3. Analytical Difficulties and Methodological Solutions in Quality Studies

Impurity analysis of carbocisteine has three inherent difficulties: the main component and most impurities are amino acid-type compounds with highly similar physicochemical properties, making chromatographic separation difficult; the molecule lacks a UV chromophore and usually requires derivatization with ninhydrin or o-phthalaldehyde (OPA) for detection, but the derivatization scheme does not respond to organic acids or cyclized products that do not react with the derivatization reagent; the European Pharmacopoeia has long used ninhydrin color-development thin-layer chromatography to evaluate the impurity profile, which can only detect amino acid-type substances, whereas the related substances produced during synthesis and degradation are not all amino acids, resulting in some impurities being undetectable or having high detection limits that are difficult to meet current impurity control requirements.

The current solution is mixed-mode chromatography (C18 hydrophobic + strong cation exchange dual retention mechanisms) combined with a charged aerosol detector (CAD), using a mass-spectrometry-compatible volatile mobile phase. The method parameters are as follows (Wahl & Holzgrabe, J Pharm Biomed Anal, 2014; Thermo Fisher AN72706 method transfer optimized version):

Table 1: Chromatographic and Detection Conditions

Table 2: Limits of Quantitation for Each Impurity (ICH Q3A(R2) reporting threshold 0.03%)

Three points should be noted during method implementation:

1. The two diastereomer chromatographic peaks of the sulfoxide are quantified by summing the peak areas;

2. Cystine is the main limitation of the original method, with an LOQ of 0.09%, higher than the 0.03% reporting threshold; some batches were judged as not detected under the original method, while the optimized method could achieve quantification in all 11 batches;

3. Chloroacetic acid is volatile and cysteine has poor stability, so neither is suitable for CAD detection, and orthogonal methods — quantitative NMR (qNMR, maleic acid internal standard) and UV/Vis spectrophotometry after Ellman's reagent color development — are needed to cover them.

An engineering-significant finding of this study is that, among 11 batch samples from 4 manufacturers, mutually distinguishing characteristic impurity profiles were observed for each manufacturer. The impurity profile can serve as a process fingerprint, and this judgment has practical evidence for carbocisteine.

4. Impurity Source Analysis

Carbocisteine is prepared by alkylation of L-cysteine with chloroacetic acid in aqueous sodium hydroxide solution. Based on this synthetic route, its impurity sources can be systematically deduced:

Table 3: Impurity Source Analysis

Another study covering 6 batches showed that the main impurities in each batch were the starting material cystine and the synthesis by-product N,S-dicarboxymethylcysteine, with purity ranging from below 99.0% to above 99.8%.

The reason cystine is difficult to remove is clearly documented in a process patent (US 4,129,593): even under conditions of complete exclusion of air and ensured quantitative reduction of the L-cystine used, the product still often contains up to 2% (mass fraction) of L-cystine, and because it is poorly soluble in water, subsequent removal is considerably difficult.

Regarding the control of chloroacetic acid (CAS 79-11-8): this compound is an α-halo carboxylic acid with clear alkylation reactivity. As a starting material, it usually requires a (Q)SAR assessment according to ICH M7 and necessary experimental confirmation, to determine whether it should be controlled as a potentially mutagenic impurity with a limit. This determination should be based on the specific process route and measured data, and should not be generalized.

5. CATO Carbocisteine Reference Standard Series

The various technical requirements above correspond to specific reference material configuration needs at the laboratory level.

Selection Notes

Oxidation products: the mixture is used for peak assignment and summed quantification, while single-configuration products are used for structural confirmation (corresponding to Section 2).

Metabolites: impurity 17 is the polymorphic metabolite described in Section 2, and is essential for sulfoxidation phenotyping and human metabolism quantification studies.

Isotope-labeled internal standards: ¹³C₃ labeling has no deuterium-hydrogen exchange risk, and is more stable than deuterated forms during prolonged sample preparation or in protic solvents.

Salt forms: an academic correspondence after the PEACE study (Lancet, 2008) pointed out that the study did not specify whether the drug form used was the sodium salt or the lysine salt — salt form has practical significance for this product.

Table 4: CATO Carbocisteine Series Reference Standard Selection Table

The above table lists commonly used products; the carbocisteine series also has several numbered impurities and salt forms in stock, and specifications and availability can be obtained by contacting CATO.

Advantageous supply of the carbocisteine series; inquiries are welcome.

References

1. Wahl O, Holzgrabe U. Impurity profiling of carbocisteine by HPLC-CAD, qNMR and UV/vis spectroscopy. J Pharm Biomed Anal. 2014;95:1-10. https://pubmed.ncbi.nlm.nih.gov/24637049/

2. Schilling K, Pawellek R, Wahl O, Holzgrabe U. HPLC-CAD impurity profiling of carbocisteine using SCX-RP mixed-mode chromatography. Thermo Fisher Scientific Application Note 72706. https://documents.thermofisher.com/TFS-Assets/CMD/Application-Notes/an-72706-hplc-cad-impurity-carbocisteine-an72706-EN.pdf

3. Carbocisteine for acute exacerbations of COPD (correspondence). Lancet. 2008. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61682-7/fulltext

4. Hoffmann U, Eichelbaum M, Seefried S, Meese CO. Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide, and (3-carboxymethylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine. https://pubmed.ncbi.nlm.nih.gov/1673403/

5. Identification of the "major" polymorphic carbocysteine metabolite as S-(carboxymethylthio)-L-cysteine. Biochem Pharmacol. https://www.sciencedirect.com/science/article/abs/pii/000629529190579T

6. Steventon GB. Diurnal variation in the metabolism of S-carboxymethyl-L-cysteine in humans. https://pubmed.ncbi.nlm.nih.gov/10460812/

7. Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action. Pharmaceutics. 2022;14(6):1261. https://www.mdpi.com/1999-4923/14/6/1261

8. S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson's Disease In Vitro Model. PMC8533464. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533464/

9. UK MHRA/SCOP review document (carbocisteine mechanism of action and pharmacokinetics section). https://assets.publishing.service.gov.uk/media/61b8c396e90e070449d49fb3/FOI_21-723-1.pdf

10. US Patent 4,129,593. Process for the production of high purity S-carboxymethyl-L-cysteine.

11. Yipinhong Pharmaceutical announcement (approval of a new specification of carbocisteine oral solution, citing Menet sales data).

12. NMPA drug approval certificate delivery information (June 11, 2024, the third carbocisteine tablet passing consistency evaluation). https://bydrug.pharmcube.com/news/detail/1646d7e367d15da4a01fa059a8de469b